Cangene appoints Michael Adelman Vice President of Commercial Operations

Focuses on building commercial business

TSX: CNJ

Readers are referred to the cautionary notes regarding Forward-looking Information at the end of this release.

WINNIPEG, Aug. 7, 2012 /CNW/ - Cangene Corporation (Cangene) announced today that it has appointed Michael D. Adelman as Vice President, Commercial Operations. Mr. Adelman is responsible for worldwide sales, marketing and distribution of Cangene's products.  He brings to the role nearly 20 years of experience in life sciences with expertise in pharmaceutical sales and marketing, strategic planning, and general management.  Mr. Adelman is based in Cangene's Pennsylvania office.

"The expansion of our commercial business, with a focus on late-stage, in-licensing opportunities to enhance our pipeline, is a key element of our corporate strategy," said John A. Sedor, President and Chief Executive Officer.  "Mike adds significant depth and experience to our sales and marketing efforts, including our planned launch of episil^® in the United States this coming October."

Mr. Adelman was previously Vice President, Marketing and Sales at Adolor Corporation where he was responsible for the marketing, market research, sales, pricing, and distribution functions of the company and leading its commercialization strategy. Prior to that, he held positions of increasing responsibility at AstraZeneca Pharmaceuticals, LP in Marketing and Sales, including Sr. Director, Marketing Strategy, Brand Director, and Regional Sales Director.  He holds an MBA from New York University, Stern School of Business and a Bachelor of Science in Business Administration, with a concentration in Finance, from Northeastern University, Boston.

About Cangene Corporation
Cangene Corporation (TSX: CNJ), headquartered in Winnipeg, Canada, is one of the nation's oldest and largest biopharmaceutical companies. It is focused on the development and commercialization of hospital and oncology clinic based therapeutics. Cangene's products are sold worldwide and include products that have been accepted into the U.S. Strategic National Stockpile. Cangene has employees in six locations across North America. It operates manufacturing facilities in Winnipeg, Manitoba and Baltimore, Maryland (through its wholly-owned subsidiary, Cangene bioPharma, Inc.) where it produces its own products and undertakes contract manufacturing for a number of customers. Cangene operates three U.S. and one Canadian plasma-collection facilities operating under the name Cangene Plasma Resources. For more information about Cangene, visit the Company's website at www.cangene.com.

Cautionary Note regarding Forward-Looking Information
This document contains forward-looking statements about the Corporation, including its business operations, strategy, and expected financial performance and condition. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as "expects", "anticipates", "intends", "plans", "will", "believes", "estimates", or negative versions thereof, and similar expressions. In addition, any statement that may be made concerning future financial performance (including revenues, earnings or growth rates), ongoing business strategies or prospects, future use, safety and efficacy of unapproved products or unapproved uses of products, and possible future action by the Corporation are also forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and are inherently subject to, among other things, risks, uncertainties and assumptions about the Corporation, economic factors and the biopharmaceutical industry generally. They are not guarantees of future performance. Actual events and results could differ materially from those expressed or implied by forward-looking statements made by the Corporation due to, but not limited to, important factors such as sales levels; fluctuations in operating results; the Corporation's reliance on a small number of customers including government organizations; the demand for new products and the impact of competitive products, service and pricing; the availability and cost of raw materials, and in particular, the cost, availability and antibody concentration in plasma; progress and cost of clinical trials; costs and possible development delays resulting from use of legal, regulatory or legislative strategies by the Company's competitors; uncertainty related to intellectual property protection and potential costs associated with its defence as well as general economic, political and market factors in North America and internationally; interest and foreign exchange rates; business competition; technological change; changes in government action, policies or regulations; decisions by Health Canada, the United States Food and Drug Administration and other regulatory authorities regarding whether and when to approve drug applications that have been or may be filed, as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of drug candidates; unexpected judicial or regulatory proceedings; catastrophic events; the Corporation's ability to complete strategic transactions; and other factors beyond the control of management.

The reader is cautioned that the foregoing list of important factors is not exhaustive and there may be other factors listed in other filings with securities regulators, including factors set out under "Risk and Uncertainties" in the Corporation's Management Discussion and Analysis, which, along with other filings, is available for review at www.sedar.com. The reader is also cautioned to consider these and other factors carefully and not to place undue reliance on forward-looking statements. Other than as specifically required by applicable law, the Corporation has no intention to update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Cangene Corporation

Contact Information
Francis J. St.Hilaire
Vice President, General Counsel & Secretary
Ph:  [phone]
Email: [email protected]